Boehringer Ingelheim adds second AI partner in a month
Three weeks after signing a deal with one AI-focused biotech, Boehringer Ingelheim is adding another.
The German pharma has announced a partnership with BERG, the data analysis and Bayesian AI company founded over a decade ago by real estate billionaire Carl Berg. Berg will use its computer and wet lab platform to investigate inflammatory diseases, most notably attempting coming up with causes, biomarkers, drug targets and drugs for inflammatory bowel disease and Crohn’s disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.